PE20180951A1 - Compuestos de hidroxitriazina y usos medicos de los mismos - Google Patents
Compuestos de hidroxitriazina y usos medicos de los mismosInfo
- Publication number
- PE20180951A1 PE20180951A1 PE2018000185A PE2018000185A PE20180951A1 PE 20180951 A1 PE20180951 A1 PE 20180951A1 PE 2018000185 A PE2018000185 A PE 2018000185A PE 2018000185 A PE2018000185 A PE 2018000185A PE 20180951 A1 PE20180951 A1 PE 20180951A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- alkoxy
- formula
- hydrogen
- hydroxythriazine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Referido a un compuesto de la formula [I-a], [I-b], o [I-c], caracterizado porque R1 es la formula (1), en donde R1a es alquilo C1-4; R1b es alquilo C1-4, o trifluorometilo, y R1c es alquilo C1-4, fluoroalquilo C1-4, alcoxi C1-4, o alcoxi C1-4-alquilo C1-4; o la formula (2), en donde n es 1, 2, 3, 4 o 5, y R1d es fluoro, alquilo C1-4, fluoroalquilo C1-4, alcoxi C1-4, o alcoxi C1-4-alquilo C1-4. R2 es hidrogeno o alquilo C1-4. R3 es hidrogeno, halogeno, alquilo C1-4, o alcoxi C1-4. R4 es la formula (3), en donde R4a es hidrogeno, alquilo C1-4 o alcoxi C1-4, o la formula (4), en donde R5 es alquilo C1-6, R6 es alquilo C1-6, cicloalquilo C3-5, o alcoxi C1-4-alquilo C1-4. X es CH2 u O, siempre que, cuando R2 en la formula (I-a) es alquilo C1-4, entonces R3 sea hidrogeno. Este, es un compuesto de hidroxitriazina y tiene una actividad inhibidora sobre la prostaglandina microsomal E2 sintasa-1 (mPGES-1), y es de utilidad para la prevencion o el tratamiento de dolor, reumatismo, osteoartritis, glaucoma, esclerodermia sistemica y/o cancer incluyendo cancer colorrectal, entre otros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015160284 | 2015-08-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20180951A1 true PE20180951A1 (es) | 2018-06-11 |
Family
ID=58052084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000185A PE20180951A1 (es) | 2015-08-17 | 2016-08-16 | Compuestos de hidroxitriazina y usos medicos de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20170057943A1 (es) |
| EP (2) | EP4046991A1 (es) |
| JP (4) | JP2017039714A (es) |
| KR (1) | KR20180037270A (es) |
| CN (1) | CN108137515B (es) |
| AR (1) | AR105711A1 (es) |
| AU (1) | AU2016309337B2 (es) |
| BR (1) | BR112018001809A2 (es) |
| CA (1) | CA2992410A1 (es) |
| CL (1) | CL2018000430A1 (es) |
| CO (1) | CO2018002516A2 (es) |
| IL (1) | IL257559B (es) |
| MX (1) | MX2018002044A (es) |
| PE (1) | PE20180951A1 (es) |
| PH (1) | PH12018500181A1 (es) |
| SG (1) | SG11201800698VA (es) |
| TW (1) | TWI704139B (es) |
| WO (1) | WO2017030115A1 (es) |
| ZA (1) | ZA201801134B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20180951A1 (es) * | 2015-08-17 | 2018-06-11 | Japan Tobacco Inc | Compuestos de hidroxitriazina y usos medicos de los mismos |
| CN108137513B (zh) * | 2015-10-29 | 2022-03-01 | Aska 制药株式会社 | 嘧啶衍生物 |
| RU2648181C1 (ru) * | 2017-05-25 | 2018-03-22 | Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации | Способ лечения нейроретинопатии вследствие тяжелой преэклампсии |
| CN110799506B (zh) * | 2017-06-26 | 2024-03-01 | 默克专利有限公司 | 用于制备被取代的含氮杂环化合物的方法 |
| TW202409037A (zh) * | 2022-07-06 | 2024-03-01 | 日商Ａｓｋａ製藥股份有限公司 | 嘧啶衍生物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2138488A1 (en) * | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| GB2463788B (en) * | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
| CN101747282A (zh) * | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| CA2811154C (en) * | 2009-09-23 | 2019-01-08 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
| AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| PE20180951A1 (es) * | 2015-08-17 | 2018-06-11 | Japan Tobacco Inc | Compuestos de hidroxitriazina y usos medicos de los mismos |
-
2016
- 2016-08-16 PE PE2018000185A patent/PE20180951A1/es unknown
- 2016-08-16 EP EP22162814.2A patent/EP4046991A1/en active Pending
- 2016-08-16 SG SG11201800698VA patent/SG11201800698VA/en unknown
- 2016-08-16 TW TW105126071A patent/TWI704139B/zh active
- 2016-08-16 KR KR1020187007349A patent/KR20180037270A/ko not_active Application Discontinuation
- 2016-08-16 CA CA2992410A patent/CA2992410A1/en active Pending
- 2016-08-16 EP EP16837104.5A patent/EP3339296A4/en not_active Withdrawn
- 2016-08-16 AR ARP160102503A patent/AR105711A1/es unknown
- 2016-08-16 BR BR112018001809-0A patent/BR112018001809A2/pt not_active Application Discontinuation
- 2016-08-16 JP JP2016159454A patent/JP2017039714A/ja not_active Ceased
- 2016-08-16 CN CN201680060597.6A patent/CN108137515B/zh active Active
- 2016-08-16 MX MX2018002044A patent/MX2018002044A/es active IP Right Grant
- 2016-08-16 US US15/237,763 patent/US20170057943A1/en not_active Abandoned
- 2016-08-16 WO PCT/JP2016/073879 patent/WO2017030115A1/ja active Application Filing
- 2016-08-16 AU AU2016309337A patent/AU2016309337B2/en active Active
-
2018
- 2018-01-24 PH PH12018500181A patent/PH12018500181A1/en unknown
- 2018-02-15 IL IL257559A patent/IL257559B/en unknown
- 2018-02-16 CL CL2018000430A patent/CL2018000430A1/es unknown
- 2018-02-19 ZA ZA2018/01134A patent/ZA201801134B/en unknown
- 2018-03-12 CO CONC2018/0002516A patent/CO2018002516A2/es unknown
-
2020
- 2020-03-03 US US16/807,719 patent/US20210024486A1/en not_active Abandoned
- 2020-09-04 JP JP2020148973A patent/JP2020193235A/ja not_active Ceased
-
2022
- 2022-08-12 JP JP2022128590A patent/JP2022163169A/ja active Pending
-
2023
- 2023-02-24 US US18/114,043 patent/US20240076278A1/en active Pending
- 2023-12-08 JP JP2023207429A patent/JP2024019449A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4046991A1 (en) | 2022-08-24 |
| US20170057943A1 (en) | 2017-03-02 |
| MX2018002044A (es) | 2018-04-13 |
| TWI704139B (zh) | 2020-09-11 |
| RU2018109220A (ru) | 2019-09-19 |
| CN108137515B (zh) | 2021-07-06 |
| EP3339296A4 (en) | 2019-01-23 |
| US20240076278A1 (en) | 2024-03-07 |
| JP2020193235A (ja) | 2020-12-03 |
| AU2016309337A1 (en) | 2018-02-01 |
| JP2024019449A (ja) | 2024-02-09 |
| AR105711A1 (es) | 2017-11-01 |
| US20210024486A1 (en) | 2021-01-28 |
| EP3339296A1 (en) | 2018-06-27 |
| IL257559B (en) | 2021-07-29 |
| AU2016309337B2 (en) | 2021-03-04 |
| CO2018002516A2 (es) | 2018-05-31 |
| PH12018500181A1 (en) | 2018-07-30 |
| JP2022163169A (ja) | 2022-10-25 |
| TW201718524A (zh) | 2017-06-01 |
| ZA201801134B (en) | 2019-07-31 |
| CN108137515A (zh) | 2018-06-08 |
| CL2018000430A1 (es) | 2018-08-03 |
| SG11201800698VA (en) | 2018-03-28 |
| JP2017039714A (ja) | 2017-02-23 |
| CA2992410A1 (en) | 2017-02-23 |
| IL257559A (en) | 2018-04-30 |
| RU2018109220A3 (es) | 2019-11-15 |
| WO2017030115A1 (ja) | 2017-02-23 |
| KR20180037270A (ko) | 2018-04-11 |
| BR112018001809A2 (pt) | 2018-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180951A1 (es) | Compuestos de hidroxitriazina y usos medicos de los mismos | |
| PE20171329A1 (es) | Agentes inmunorreguladores | |
| AR108768A2 (es) | Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina | |
| EA201991161A1 (ru) | 7-фенилэтиламино-4h-пиримидо[4,5-d][1,3]оксазин-2-оновые соединения в качестве ингибиторов мутантных idh1 и idh2 | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CL2017001050A1 (es) | Nuevos compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| CL2016000466A1 (es) | Compuestos derivados de 2-amino pirimidina sustituida, inhibidores de bmi-1 composicion farmaceutica y uso en el tratamiento del cancer. | |
| ECSP15053445A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
| PE20040411A1 (es) | Compuestos de aril cetona pirrolo triazina | |
| PE20181345A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer | |
| AR081628A1 (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
| CO2018003367A2 (es) | Benzamidas sustituidas con isoxazolina y análogos como insecticidas | |
| EA201892415A1 (ru) | Полиморфная форма n-{6-(2-гидроксипропан-2-ил)-2-[2-(метилсульфонил)этил]-2н-индазол-5-ил}-6-(трифторметил)пиридин-2-карбоксамида | |
| PE20211548A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| PE20170129A1 (es) | Compuestos de pirazol y su uso como bloqueadores de los canales de calcio tipo t | |
| CL2017001467A1 (es) | Compuestos de dihidropirimidin - 2 - ona y sus usos médicos | |
| EA201990158A1 (ru) | Производные бензодиоксана и их фармацевтическое применение | |
| MX2017016096A (es) | Agente antihipertensivo. | |
| EA201991595A1 (ru) | Активатор nrf2 | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| EA201691566A1 (ru) | Применение производных пиридазина для предупреждения или лечения атаксического синдрома | |
| NI201800065A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer | |
| PH12018500668A1 (en) | Therapeutic compounds and methods of use thereof |